US92337R1014 - Common Stock - After market: 22.19 0 (0%)
NASDAQ:VERA (10/4/2022, 7:00:32 PM)+1.78 (+8.72%)
|GICS Sector||Health Care|
|Earnings (Last)||08-10 2022-08-10/bmo||Earnings (Next)||N/A N/A|
|Ins Owners||12.73%||Inst Owners||78.97%|
Find more stocks on Nasdaq
Find more stocks on the USA
Find competitors from the same sector on the USA
Find competitors from the same industry on the USA
Find stocks with similar TA and Setup ratings on the USA
Find stocks with similar Fundamental rating on the USA
Find the competitors with the best technical ratings on the USA
Find the competitors with the best technical and setup ratings on the USA
Find the competitors with the best fundamentals on the USA
Find the competitors with the best valuation on the USA
Find the competitors with the best dividend on the USA
Find the competitors with the best analyst ratings on the USA
Vera Therapeutics, Inc. is a clinical stage biotechnical company that engages in the development and commercialization of transformative treatments for immunological diseases. The company is headquartered in Brisbane California, California and currently employs 29 full-time employees. The company went IPO on 2021-05-14. The firm is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Its lead product candidate, atacicept, a self-administered fusion protein that blocks both B lymphocyte stimulator (BLyS) and a proliferation inducing ligand (APRIL), which stimulates B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases. Atacicept is being developed for the treatment of immunoglobulin A nephropathy (IgAN), a rare autoimmune disease that can lead to dialysis, kidney transplant, serious disease, and early death. The company is also developing MAU868, a monoclonal antibody that neutralizes infection with BK Virus. The firm is also planning to initiate a Phase III clinical trial of atacicept as a potential treatment for patients with LN, a severe renal manifestation of Systemic Lupus Erythematosus (SLE).
VERA THERAPEUTICS INC
8000 Marina Boulevard, Suite 120, 3Rd Floor
Brisbane California CALIFORNIA 14623
CEO: Marshall Fordyce
BRISBANE, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and...
Completed enrollment for Phase 2b ORIGIN clinical trial of atacicept in IgA nephropathy; topline data now expected to be presented in early Q1...
BRISBANE, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and...
Topline results anticipated fourth quarter of 2022...
MAU868, a first-in-class monoclonal antibody, was well tolerated in kidney transplant recipients with BK viremiaData presented as oral late breaker at...
BRISBANE, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and...
Here you can normally see the latest stock twits on VERA, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.